Market Access Are timely access and robust safety mutually exclusive? The FDA approves new cancer treatments in half the time of the EMA – but does faster mean better? And how can regulators balance timely access with robust safety?
News Sobi plans filings for gout drug after phase 3 readout SEL-212 will compete with Horizon's fast-growing Krystexxa if approved by the FDA.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK